{"id": "chatcmpl-8JYRV1ksqpkZ8xbkJC9enrw2bzdAn", "object": "chat.completion", "created": 1699671321, "model": "gpt-4-0613", "choices": [{"index": 0, "message": {"role": "assistant", "content": "1. Free PCSK9 concentrations were lowest at day 71 in all groups.\n2. Free PCSK9 concentrations increased over time after day 71.\n3. By day 85, free PCSK9 concentrations were higher.\n4. Alirocumab levels were lower by day 85.\n5. Free PCSK9 concentrations were higher with alirocumab plus fenofibrate by day 85.\n6. Free PCSK9 concentrations were higher to a lesser extent with alirocumab plus ezetimibe by day 85.\n7. Alirocumab levels were lower with alirocumab plus fenofibrate by day 85.\n8. Alirocumab levels were lower to a lesser extent with alirocumab plus ezetimibe by day 85.\n9. The changes in free PCSK9 concentrations and alirocumab levels were compared against alirocumab plus placebo."}, "finish_reason": "stop"}], "usage": {"prompt_tokens": 102, "completion_tokens": 189, "total_tokens": 291}, "temperature": 0, "max_tokens": 512, "top_p": 1, "frequency_penalty": 0, "presence_penalty": 0, "messages": [{"role": "system", "content": "Statement: Free PCSK9 concentrations were lowest at day 71 in all groups, then increased over time; by day 85, free PCSK9 concentrations were higher, and alirocumab levels lower, with alirocumab plus fenofibrate, and to a lesser extent alirocumab plus ezetimibe, versus alirocumab plus placebo.\n\nList all the facts we explicitly know from the statement. Make each fact as atomic as possible."}]}